Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies., PMID:40280128
Design of immunogens to present a tumor-specific cryptic epitope., PMID:40175576
Expanding the Therapeutic Reach of Chimeric Antigen Receptor T-Cells and Bispecific T-Cell Engagers Across Solid Tumors., PMID:40138603
Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation., PMID:39947814
Isolation and Characterization of the First Antigen-Specific EGFRvIII vNAR from Freshwater Stingray (Potamotrygon spp.) as a Drug Carrier in Glioblastoma Cancer Cells., PMID:39940647
A Bi-Specific T Cell-Engaging Antibody Shows Potent Activity, Specificity, and Tumor Microenvironment Remodeling in Experimental Syngeneic and Genetically Engineered Models of GBM., PMID:39763755
Novel tri-specific T-cell engager targeting IL-13Rα2 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells., PMID:39622583
Self-assembled nanovaccine based on apoferritin: Development and vaccine regimen evaluation., PMID:39613269
Enhanced anti-tumor efficacy of electroporation (EP)-mediated DNA vaccine boosted by allogeneic lymphocytes in pre-established tumor models., PMID:39358555
Formation of EGFRwt/EGFRvIII homo- and hetero-dimers in glioblastoma cells as detected by single molecule localization microscopy., PMID:39073345
Structural insights into the role and targeting of EGFRvIII., PMID:38908376
Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models., PMID:38743766
Preparation and evaluation of the PD0721‑DOX antibody‑drug conjugate targeting EGFRvIII to inhibit glioblastoma., PMID:38682116
Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities., PMID:38396993
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial., PMID:38216766
[Immunotherapy against gliomas]., PMID:38169045
Immunohistochemical detection of EGFRvIII in glioblastoma - Anti-EGFRvIII antibody validation for diagnostic and CAR-T purposes., PMID:37918325
Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements., PMID:37894718
A simplified function-first method for the discovery and optimization of bispecific immune engaging antibodies., PMID:37347762
CDR3 Variants of the TXB2 Shuttle with Increased TfR1 Association Rate and Enhanced Brain Penetration., PMID:36986599
Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape., PMID:36915911
Increased EGFRvIII Epitope Accessibility after Tyrosine Kinase Inhibitor Treatment of Glioblastoma Cells Creates More Opportunities for Immunotherapy., PMID:36901782
Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice., PMID:36898734
Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models., PMID:36753564
CAR T cells: engineered immune cells to treat brain cancers and beyond., PMID:36721153
Antibody drug conjugates, targeting cancer-expressed EGFR, exhibit potent and specific antitumor activity., PMID:36459711
Engineered anti-EGFRvIII targeted exosomes induce apoptosis in glioblastoma multiforme., PMID:36440540
[Construction of recombinant adenovirus expressing EGFRvIII extracellular domain gene and preparation of single domain antibody]., PMID:36151821
Investigating brain uptake of a non-targeting monoclonal antibody after intravenous and intracerebroventricular administration., PMID:36105215
EGFRvⅢ-targeted immunotoxin combined with temozolomide and bispecific antibody for the eradication of established glioblastoma., PMID:36095959
Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts., PMID:36071925
Programmable Attenuation of Antigenic Sensitivity for a Nanobody-Based EGFR Chimeric Antigen Receptor Through Hinge Domain Truncation., PMID:35935988
A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma., PMID:35915983
Novel Cyclic Peptides for Targeting EGFR and EGRvIII Mutation for Drug Delivery., PMID:35890400
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial., PMID:35849035
A Nanobody-on-Quantum Dot Displacement Assay for Rapid and Sensitive Quantification of the Epidermal Growth Factor Receptor (EGFR)., PMID:35759268
EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer., PMID:35626010
Visualizing Spatial and Stoichiometric Barriers to Bispecific T-Cell Engager Efficacy., PMID:35413104
Multifunctional Nanopolymers for Blood-Brain Barrier Delivery and Inhibition of Glioblastoma Growth through EGFR/EGFRvIII, c-Myc, and PD-1., PMID:34835657
Temozolomide Induces Endocytosis of EGFRvIII via p38-Mediated Non-canonical Phosphorylation in Glioblastoma Cells., PMID:34719645
Continuous Feeding Reduces the Generation of Metabolic Byproducts and Increases Antibodies Expression in Chinese Hamster Ovary-K1 Cells., PMID:34575094
High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms., PMID:34568006
Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation., PMID:34498213
EGFRvIII peptide nanocapsules and bevacizumab nanocapsules: a nose-to-brain multitarget approach against glioblastoma., PMID:34313137
A Rational Designed Novel Bispecific Antibody for the Treatment of GBM., PMID:34204931
[Consequences of extracellular alterations of EGFR on cetuximab therapy in HNSCC]., PMID:34081766
Novel high-affinity EGFRvIII-specific chimeric antigen receptor T cells effectively eliminate human glioblastoma., PMID:33976881
Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII., PMID:33632870
Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR., PMID:33517558
A Phase 1 and Biodistribution Study of ABT-806i, an 111In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806., PMID:33509972
For research use only. Not for human or drug use.
